OpGen Overview
- Year Founded
-
2001

- Status
-
Public
- Employees
-
100

- Stock Symbol
-
OPGN

- Investments
-
2
- Share Price
-
$1.38
- (As of Friday Closing)
OpGen General Information
Description
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Contact Information
Website
www.opgen.comCorporate Office
- 9717 Key West Avenue
- Suite 100
- Rockville, MD 20850
- United States
Corporate Office
- 9717 Key West Avenue
- Suite 100
- Rockville, MD 20850
- United States
OpGen Timeline
OpGen Stock Performance
As of 14-Feb-2025, OpGen’s stock price is $1.38. Its current market cap is $13.9M with 10.1M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.38 | $1.38 | $0.53 - $9.90 | $13.9M | 10.1M | 5.6K | -$15.16 |
OpGen Financials Summary
As of 30-Sep-2024, OpGen has a trailing 12-month revenue of $1.27M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 29,934 | 16,466 | 12,733 | 38,391 |
Revenue | 1,266 | 3,418 | 2,607 | 4,306 |
EBITDA | (9,176) | (29,653) | (32,431) | (27,294) |
Net Income | (9,399) | (32,669) | (37,283) | (34,806) |
Total Assets | 5,470 | 1,882 | 25,813 | 71,667 |
Total Debt | 2,241 | 13,044 | 14,822 | 25,179 |
OpGen Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
OpGen Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
OpGen Comparisons
Industry
Financing
Details
OpGen Competitors (39)
One of OpGen’s 39 competitors is Progentec, a Venture Capital-Backed company based in Oklahoma City, OK.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Progentec | Venture Capital-Backed | Oklahoma City, OK | ||||
Superfluid DX | Venture Capital-Backed | South San Francisco, CA | ||||
Strata Oncology | Venture Capital-Backed | Ann Arbor, MI | ||||
AnTolRx | Venture Capital-Backed | Cambridge, MA | ||||
DNAnexus | Venture Capital-Backed | Mountain View, CA |
OpGen Patents
OpGen Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170253917-A1 | Methods and systems for determining antibiotic susceptibility | Inactive | 07-Mar-2016 | ||
CA-3016632-A1 | Methods and systems for determining antibiotic susceptibility | Inactive | 07-Mar-2016 | ||
EP-3426800-A1 | Methods and systems for determining antibiotic susceptibility | Inactive | 07-Mar-2016 | ||
US-20160053219-A1 | Systems, methods, and devices for temperature control | Inactive | 25-Aug-2014 | ||
CA-2950327-A1 | Systems, apparatus, and methods for generating and analyzing resistome profiles | Inactive | 27-May-2014 | G16H50/80 |
OpGen Signals
OpGen Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
OpGen Acquisitions (2)
OpGen’s most recent deal was a Merger/Acquisition with Curetis. The deal was made on 01-Apr-2020.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Curetis | 01-Apr-2020 | Merger/Acquisition | Diagnostic Equipment | ||
AdvanDx | 14-Jul-2015 | Merger/Acquisition | Diagnostic Equipment |
OpGen Exits (1)
OpGen’s most recent exit was on 01-Apr-2020 from Curetis. The exit was categorized as .
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Curetis | 01-Apr-2020 | Completed |
|
OpGen FAQs
-
When was OpGen founded?
OpGen was founded in 2001.
-
Where is OpGen headquartered?
OpGen is headquartered in Rockville, MD.
-
What is the size of OpGen?
OpGen has 100 total employees.
-
What industry is OpGen in?
OpGen’s primary industry is Biotechnology.
-
Is OpGen a private or public company?
OpGen is a Public company.
-
What is OpGen’s stock symbol?
The ticker symbol for OpGen is OPGN.
-
What is the current stock price of OpGen?
As of 14-Feb-2025 the stock price of OpGen is $1.38.
-
What is the current market cap of OpGen?
The current market capitalization of OpGen is $13.9M.
-
What is OpGen’s current revenue?
The trailing twelve month revenue for OpGen is $1.27M.
-
Who are OpGen’s competitors?
Progentec, Superfluid DX, Strata Oncology, AnTolRx, and DNAnexus are some of the 39 competitors of OpGen.
-
What is OpGen’s annual earnings per share (EPS)?
OpGen’s EPS for 12 months was -$15.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »